NasdaqCM:CYRX

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Cryoport, Inc. provides temperature-controlled logistics and biostorage services to the life sciences industry in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. More Details


Snowflake Analysis

High growth potential with mediocre balance sheet.


Similar Companies

Share Price & News

How has Cryoport's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CYRX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: CYRX's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.


Market Performance


7 Day Return

13.1%

CYRX

-1.5%

US Medical Equipment

-0.9%

US Market


1 Year Return

232.3%

CYRX

20.0%

US Medical Equipment

19.6%

US Market

Return vs Industry: CYRX exceeded the US Medical Equipment industry which returned 20.5% over the past year.

Return vs Market: CYRX exceeded the US Market which returned 21% over the past year.


Shareholder returns

CYRXIndustryMarket
7 Day13.1%-1.5%-0.9%
30 Day29.9%4.9%3.0%
90 Day37.4%7.3%11.5%
1 Year232.3%232.3%21.0%20.0%22.3%19.6%
3 Year666.0%666.0%71.5%67.2%45.3%35.7%
5 Year3,118.1%3,118.1%167.2%147.2%124.8%99.9%

Long-Term Price Volatility Vs. Market

How volatile is Cryoport's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Cryoport undervalued compared to its fair value and its price relative to the market?

34.1%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: CYRX ($64.04) is trading below our estimate of fair value ($97.18)

Significantly Below Fair Value: CYRX is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: CYRX is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: CYRX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CYRX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CYRX is overvalued based on its PB Ratio (20.8x) compared to the US Medical Equipment industry average (5x).


Next Steps

Future Growth

How is Cryoport forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

98.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CYRX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).

Earnings vs Market: CYRX is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: CYRX's is expected to become profitable in the next 3 years.

Revenue vs Market: CYRX's revenue (30% per year) is forecast to grow faster than the US market (10.2% per year).

High Growth Revenue: CYRX's revenue (30% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: CYRX's Return on Equity is forecast to be low in 3 years time (13.2%).


Next Steps

Past Performance

How has Cryoport performed over the past 5 years?

-8.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CYRX is currently unprofitable.

Growing Profit Margin: CYRX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CYRX is unprofitable, and losses have increased over the past 5 years at a rate of 8.7% per year.

Accelerating Growth: Unable to compare CYRX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CYRX is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-0.3%).


Return on Equity

High ROE: CYRX has a negative Return on Equity (-18.42%), as it is currently unprofitable.


Next Steps

Financial Health

How is Cryoport's financial position?


Financial Position Analysis

Short Term Liabilities: CYRX's short term assets ($212.6M) exceed its short term liabilities ($13.2M).

Long Term Liabilities: CYRX's short term assets ($212.6M) exceed its long term liabilities ($119.1M).


Debt to Equity History and Analysis

Debt Level: CYRX's debt to equity ratio (92.6%) is considered high.

Reducing Debt: CYRX's debt to equity ratio has increased from 14.3% to 92.6% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CYRX has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if CYRX has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Cryoport current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CYRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CYRX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CYRX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CYRX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CYRX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.0yrs

Average management tenure


CEO

Jerrell Shelton (75 yo)

8.17yrs

Tenure

US$4,184,464

Compensation

Mr. Jerrell W. Shelton, also known as Jerry, has been the Chief Executive Officer and President of CryoPort, Inc. since November 5, 2012 and has been its Chairman of the Board since October 2015. Mr. Shelt...


CEO Compensation Analysis

Compensation vs Market: Jerrell's total compensation ($USD4.18M) is about average for companies of similar size in the US market ($USD4.98M).

Compensation vs Earnings: Jerrell's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Jerrell Shelton
Chairman8.17yrsUS$4.18m1.24%
$ 31.6m
Robert Stefanovich
CFO, Treasurer & Corporate Secretary9.58yrsUS$1.21m0.0025%
$ 64.1k
Tony Ippolito
VP & General Counselno datano datano data
Thomas Heinzen
Vice President of Corporate Developmentno datano datano data
Bret Bollinger
Chief Technology Officer of Cryoport Systems1yrUS$174.52kno data
Phil Wilson
Chief Operating Officer of Cryoport Systems1yrno datano data
Mark Sawicki
President & CEO of Cryoport Systems1yrno datano data
Raymond Takahashi
Executive Officerno datano datano data
David Petreccia
Executive Officerno datano datano data

1.0yrs

Average Tenure

55yo

Average Age

Experienced Management: CYRX's management team is not considered experienced ( 1 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Jerrell Shelton
Chairman8.17yrsUS$4.18m1.24%
$ 31.6m
Richard Berman
Independent Lead Director5.17yrsUS$411.41k0.023%
$ 592.5k
William Taaffe
Member of Commercial Advisory Board8yrsno datano data
Edward Zecchini
Independent Director7.33yrsUS$381.41k0.088%
$ 2.2m
Robert Hariri
Independent Director5.33yrsUS$390.41k0.077%
$ 2.0m
Ram Jagannath
Director0.25yrno datano data
Rick Kriss
Member of Advisory Board13yrsno datano data
Larry O'Toole
Member of Advisory Boardno datano datano data
Ramkumar Mandalam
Independent Director6.58yrsUS$376.41k0.051%
$ 1.3m
Daniel Hancock
Independent Director2yrsUS$837.66k0.011%
$ 281.7k

5.3yrs

Average Tenure

70yo

Average Age

Experienced Board: CYRX's board of directors are considered experienced (5.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: CYRX insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10.8%.


Top Shareholders

Company Information

Cryoport, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Cryoport, Inc.
  • Ticker: CYRX
  • Exchange: NasdaqCM
  • Founded: 1999
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$2.543b
  • Shares outstanding: 39.70m
  • Website: https://www.cryoport.com

Number of Employees


Location

  • Cryoport, Inc.
  • 112 Westwood Place
  • Suite 350
  • Brentwood
  • Tennessee
  • 37027
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CYRXNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDJan 2005

Biography

Cryoport, Inc. provides temperature-controlled logistics and biostorage services to the life sciences industry in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two seg...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/01/16 00:54
End of Day Share Price2021/01/15 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.